---
title: "U.S. stock night market opening fluctuations: Steakholder Foods fell 6.31% in the night market; Skye Bioscience rose 5.28% in the night market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296156995.md"
description: "Steakholder Foods fell 6.31% in after-hours trading; Skye Bioscience rose 5.28% in after-hours trading; Amylyx Pharmaceuticals rose 15.54% in after-hours trading; Jiufu Group rose 12.07% in after-hours trading; Fundrise Innovation Fund LLC rose 6.39% in after-hours trading"
datetime: "2026-08-18T00:12:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296156995.md)
  - [en](https://longbridge.com/en/news/296156995.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296156995.md)
generator: "portal-rs"
---

# U.S. stock night market opening fluctuations: Steakholder Foods fell 6.31% in the night market; Skye Bioscience rose 5.28% in the night market

**U.S. Stock Night Market Opening Movements**

Steakholder Foods fell 6.31% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Skye Bioscience rose 5.28% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

**Top Gainers in the U.S. Night Market**

Amylyx rose 15.54% in the night market. Based on recent key news:

1.  On August 18, Amylyx Pharmaceuticals announced it would release top-line results from a Phase 3 trial for postoperative hypoglycemia. This news drove the stock price up 15% to $24.58. The FDA has granted the drug breakthrough therapy and orphan drug status, boosting market confidence.

2.  On August 18, Mizuho analyst Graig Suvannavejh raised Amylyx's target price from $24 to $30 and maintained an "Outperform" rating. The analyst believes that if the Phase 3 data is positive, there is further upside potential for the stock price.

3.  On August 18, market sentiment towards Amylyx shifted from bearish to bullish, with a significant increase in discussions on social platforms. Investors expect the trial results to drive the stock price further up. The biopharmaceutical industry has been active recently, with investors focusing on new drug development progress.

Jiufu Group rose 12.07% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Fundrise Innovation Fund LLC rose 6.39% in the night market. There is no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no\_news

### Related Stocks

- [STKH.US](https://longbridge.com/en/quote/STKH.US.md)
- [SKYE.US](https://longbridge.com/en/quote/SKYE.US.md)
- [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md)
- [JFU.US](https://longbridge.com/en/quote/JFU.US.md)
- [VCX.US](https://longbridge.com/en/quote/VCX.US.md)

## Related News & Research

- [Cocoa Crashed This Year. So Why Is Your Halloween Candy Still This Pricey?](https://longbridge.com/en/news/298054892.md)
- [Procter & Gamble (PG) Could Be 37% Above Fair Value After New Product Launches](https://longbridge.com/en/news/298073923.md)
- [Michael Burry Warns of a Private Credit 'Shell Game' That Could Leave Taxpayers on the Hook: APO, KKR, OWL In Focus](https://longbridge.com/en/news/297885152.md)
- [Robinhood Chain Could Force Wall Street To Rethink Arbitrum](https://longbridge.com/en/news/297944555.md)
- [Why the jobs report will actually be good for bonds](https://longbridge.com/en/news/298066649.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**